Assessments
intracranial disease, SD, Tumor
DISEASE, BRAIN METASTASES, TUMOR
Tumor responses were evaluated by investigators and IRC per RECIST v1.1 using computed tomography (CT) or magnetic resonance imaging (MRI) within 2 weeks of study entry, at 6 weeks post-treatment, and once every two cycles thereafter. Complete response (CR), partial response (PR), and stable disease (SD) had to be confirmed with a repeat scan after at least 6 weeks. The response of intracranial disease was evaluated radiologically per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM). AEs were evaluated using NCI-CTC AE version 5.0.